ProCyte Corporation Announces Investor Relations Initiatives

Business Wire, Jan 27, 2004

Business Editors

REDMOND, Wash.--(BUSINESS WIRE)--Jan. 27, 2004

ProCyte Corporation (OTCBB:PRCY.OB), a dermatology and cosmetic surgery products company, today announced several new investor relations activities for the first quarter of 2004 designed to increase exposure for the company.

Jack Clifford, President of ProCyte, will be participating in a series of weekly interviews with Steve Crowley on his American Scene radio program heard nationally on the Cable Radio Network and the Business Talk Radio Network. The series of interviews offer an opportunity to present the ProCyte growth story to a large national audience of investors interested in small cap companies. Information about the American Scene program and the local stations where the program is broadcast can be found at www.americansceneradio.com.

In addition, Mr. Clifford will be presenting an overview of the company at The Wall Street Analyst Forum New York City Analysts Conference on Monday, March 1, 2004 at 11:40 AM. "This is the first time ProCyte has presented at this conference," said Jack Clifford, President and CEO. "We are excited to have this opportunity to speak directly to a broad spectrum of analysts and interested investors." Approximately 100 public companies will make presentations at the conference, which runs from March 1, 2004 through March 3, 2004 at the Roosevelt Hotel in New York. The program will be webcast live and be available for later replay. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at 802-253-7596 to request additional information.

The Company has been mentioned in recent articles about anti-aging skin care and prestige beauty markets published by the Wall Street Journal and several consumer publications. Mr. Clifford was also recently interviewed by the Wall Street Reporter for an article on the current trends and future prospects for the company and the industry. The article is expected to be published by the end of January and may be accessed on www.wallstreetreporter.com after that time.

As part of its new increased awareness plan, the Company has also decided to bring more of its investor relations activities in house to allow for more focused interaction with management. Effective February 1, 2004 all investor relation inquiries can be directed to Investor Relations, ProCyte Corporation at 425-869-1239, extension 399 or irinfo@procyte.com.

ProCyte Corporation develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to dermatologists, plastic and cosmetic surgeons, spas and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte's products include Neova(R), VitalCopper(TM), Simple Solutions(R) and AquaSante(R) Skin Care products; Complex Cu3(R) Post-Procedure Skin Care; GraftCyte(R) Hair Transplant Care; and Tricomin(R) Advanced Care for Thinning Hair. The Company also has the exclusive distribution rights for Cutanix Corporation's Quadrinone(R) technology for medical and spa markets in the U.S., Canada and Puerto Rico. Additional information is available by visiting the Company's website at www.procyte.com.

This release may contain forward-looking statements relating to the research, development, commercialization, production, marketing and distribution of the Company's products and future operating results, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include its ability to develop, commercialize and produce new products; the market acceptance of existing and potential future products; the availability, cost and timely delivery of materials and services from and performance of third-party suppliers, manufacturers, distributors, licensees and other collaborative partners; the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals. Reference is made to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and its latest Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.